{"nctId":"NCT01693029","briefTitle":"Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa","startDateStruct":{"date":"2012-09"},"conditions":["Anemia","Chronic Kidney Disease (CKD)"],"count":435,"armGroups":[{"label":"HX575 epoetin alfa","type":"EXPERIMENTAL","interventionNames":["Drug: HX575 epoetin alfa"]},{"label":"US-licensed epoetin alfa","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: US-licensed epoetin alfa"]}],"interventions":[{"name":"HX575 epoetin alfa","otherNames":["Binocrit® (Europe)","Epoetin alfa HEXAL® (Europe)","Abseamed® (Europe)"]},{"name":"US-licensed epoetin alfa","otherNames":["Epogen®","Procrit®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with end stage renal disease (stage CKD 5d), receiving stable subcutaneous maintenance therapy with Epogen® or Procrit® at least once per week\n* Mean hemoglobin level between 9.0 - 11.5 g/dL during the screening period\n* Adequate iron substitution\n\nExclusion Criteria:\n\n* Contraindications for Erythropoiesis Stimulating Agent (ESA) therapy\n* History of Pure Red Cell Aplasia (PRCA), or anti-erythropoietin (EPO) antibodies\n* Known Human Immunodeficiency Virus (HIV) or Hepatitis B infection\n* Hepatitis C infection on an active treatment\n* Symptomatic congestive heart failure (New York Heart Association \\[NYHA\\] class III and IV)\n* Unstable angina pectoris, or cardiac infarction during the last 6 months prior to randomization\n* Percutaneous coronary intervention, or coronary artery bypass grafting during the last 6 months prior to randomization\n* History of malignancy of any organ system\n* Systemic lupus erythematous\n* Immunocompromized patients\n\nOther In-/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Absolute Change in Hemoglobin Levels Between the Screening/Baseline Period (Week -4 to Day 1) and the Evaluation Period (Week 21-28)","description":"Response to epoetin alfa in anemic patients with chronic renal failure is manifested by increased hematocrit, hemoglobin, reduced transfusion requirements and increase in quality of life. Hemoglobin (laboratory haematology parameter) is the primary endpoint of the study .","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0960","spread":"0.0575"},{"groupId":"OG001","value":"-0.0035","spread":"0.0573"}]}]}]},{"type":"PRIMARY","title":"Change in Mean Hb Level Between Baseline (Week -4 to Day1) and Evaluation Period (Week 21-28)","description":"Response to epoetin alfa in anemic patients with chronic renal failure is manifested by increased hematocrit, hemoglobin, reduced transfusion requirements and increase in quality of life. Hemoglobin (laboratory haematology parameter) is the primary endpoint of the study .","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.53","spread":"0.635"},{"groupId":"OG001","value":"10.50","spread":"0.615"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.42","spread":"0.826"},{"groupId":"OG001","value":"10.51","spread":"0.873"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"1.011"},{"groupId":"OG001","value":"0.01","spread":"0.953"}]}]}]},{"type":"SECONDARY","title":"Mean Weekly Dose During Evaluation Period (Week 21-28)","description":"Mean weekly study drug dose during evaluation period (Week 21-28)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5876.5","spread":"5785.50"},{"groupId":"OG001","value":"5804.0","spread":"6343.70"}]}]}]},{"type":"SECONDARY","title":"Incidence of Antibody Formation Against Epoetin","description":"Number of patients with positive antidrug antibody (ADA) finding at any time during their treatment period. Count includes 2 patients (1 in each arm) that already had a positive ADA Baseline finding. ADA testing performed by by Radio-Immuno-Precipitation assay. No patient developed neutralizing antibodies.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":91,"n":217},"commonTop":["Hypertension","Diarrhoea","Nausea","Upper respiratory tract infection","Fall"]}}}